Prenatal testing is any medical test performed during pregnancy to assess the health of the developing baby, the risk of chromosomal conditions, or the presence of structural abnormalities. These tests range from simple blood draws and ultrasounds that screen for potential problems to procedures like amniocentesis that can deliver definitive diagnoses. The timing spans nearly the entire pregnancy, with different tests slotting into specific windows from as early as nine or ten weeks through the third trimester. Understanding what each test does and when it happens helps you make informed choices about which ones, if any, are right for your pregnancy.
First-Trimester Screening
The earliest widely offered screening typically happens between about 11 and 14 weeks. It combines a blood draw with an ultrasound measurement. The blood test checks levels of two proteins: PAPP-A and free beta-hCG. In pregnancies affected by Down syndrome, PAPP-A tends to run low while free beta-hCG runs high. In trisomy 18, both markers tend to be decreased.1PubMed. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities The ultrasound part measures the fluid-filled space at the back of the baby’s neck, called nuchal translucency. A thicker-than-expected measurement can signal chromosomal conditions or heart defects.
What makes first-trimester screening powerful is the combination. Either the blood work or the ultrasound alone catches some affected pregnancies, but together their detection rates exceed what second-trimester blood screening alone can achieve.2PubMed. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency Keep in mind that this is still a screening test: it estimates your risk rather than giving a definitive answer. A “high-risk” result does not mean the baby has a chromosomal condition. It means further testing, usually cell-free DNA screening or an invasive diagnostic procedure, is recommended.
Second-Trimester Blood Screening
If you missed first-trimester screening or your provider follows a different protocol, a second-trimester blood test is typically offered between 15 and 22 weeks. The most common version measures three or four markers in your blood: alpha-fetoprotein (AFP), hCG, unconjugated estriol, and sometimes inhibin A. These markers help estimate risk for Down syndrome, trisomy 18, and open neural tube defects like spina bifida.3PubMed Central. External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester
The second-trimester screen has been a mainstay of prenatal care for decades, though its detection rates for chromosomal conditions are generally lower than first-trimester combined screening or cell-free DNA testing. Its biggest remaining advantage is neural tube defect screening via AFP, which is not directly addressed by cell-free DNA tests. Some providers offer “integrated” or “sequential” screening that merges first- and second-trimester blood results for improved accuracy overall.
Non-Invasive Prenatal Testing
Non-invasive prenatal testing, commonly called NIPT or cell-free DNA screening, has reshaped prenatal care since its clinical introduction in the early 2010s. A simple blood draw from the pregnant person, available from around nine or ten weeks onward, analyzes fragments of DNA that the placenta sheds into the mother’s bloodstream.4PubMed. Circulating fetal DNA: its origin and diagnostic potential-a review These fragments reflect the baby’s genetic makeup and can be screened for extra or missing chromosomes.
For the three most common trisomies, NIPT is remarkably accurate. A large meta-analysis found pooled sensitivity of about 99% for Down syndrome, 97% for Edwards syndrome (trisomy 18), and 97% for Patau syndrome (trisomy 13), with specificity above 99.9% for all three.5BMJ Open. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis Those numbers sound nearly perfect, and in terms of catching truly affected pregnancies, NIPT rarely misses. But the flip side matters too: how often does a “positive” result turn out to be wrong?
That depends on the condition. In one laboratory review, the positive predictive value for trisomy 21 was about 86%, meaning roughly 14 out of 100 women told they screened high-risk for Down syndrome actually carried an unaffected pregnancy. For trisomy 18 the positive predictive value dropped to about 58%, and for trisomy 13 it was around 25%.6PubMed Central. Positive predictive value estimates for noninvasive prenatal testing from data of a prenatal diagnosis laboratory and literature review That gap between a test’s sensitivity and its real-world predictive value catches many people off guard. For rarer conditions, a positive NIPT result is wrong more often than it is right, which is why professional guidelines emphasize that NIPT is a screening test, not a diagnosis, and that a positive result should always be confirmed with an invasive procedure before irreversible decisions are made.
Why NIPT Sometimes Gets It Wrong
The DNA fragments floating in maternal blood come predominantly from the placenta, not directly from the baby. Most of the time placental DNA mirrors fetal DNA, but not always. The most common reason for a false NIPT result is confined placental mosaicism, a situation where placental cells carry a chromosomal abnormality that the baby does not share, or vice versa.7PubMed Central. Discrepancy between non-invasive prenatal testing result and fetal karyotype caused by rare confined placental mosaicism: A case report
Other factors can also skew results. A low fetal fraction, meaning the baby’s DNA makes up a small share of the total cell-free DNA, is more common in people with a higher body mass index and can lead to missed findings. Maternal conditions such as a previously undetected chromosomal variation or even an occult tumor can produce false-positive signals. Situations like a vanishing twin, where a second embryo stopped developing early in pregnancy, can leave behind extra DNA fragments that confuse the analysis.8PubMed Central. Chromosomal structural abnormalities and tissue-specific mosaicism: insights into false-negative noninvasive prenatal testing Understanding these biological quirks helps explain why a screening test with 99% sensitivity can still produce a meaningful number of incorrect results in the real world.
NIPT for Microdeletions and Sex Chromosomes
Many commercial NIPT panels now offer optional screening beyond the common trisomies, including sex chromosome conditions and microdeletion syndromes. The most frequently screened microdeletion is 22q11.2 deletion syndrome (also known as DiGeorge syndrome), which occurs in roughly 1 in 2,000 to 4,000 live births regardless of maternal age. Early validation work using a technology based on single-nucleotide polymorphisms reported detection rates above 90% for 22q11.2 deletion with very low false-positive rates.9PubMed. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes
Real-world clinical experience, however, has been more sobering. One study found that when NIPT flagged a pregnancy as high-risk for 22q11.2 deletion, only about 18% of confirmed follow-up cases were true positives, meaning more than 80% were false alarms.10PubMed Central. Clinical experience with single‐nucleotide polymorphism‐based non‐invasive prenatal screening for 22q11.2 deletion syndrome A separate validation study using a different cohort found sensitivity of 90% and specificity near 99.7%, with a similarly low positive predictive value.11PLOS ONE. Validation of a SNP-based non-invasive prenatal test to detect the fetal 22q11.2 deletion in maternal plasma samples The underlying problem is prevalence: when a condition is rare, even a highly specific test will generate many false positives relative to the small number of true cases. If your NIPT panel includes microdeletion screening and a result comes back high-risk, genetic counseling and diagnostic confirmation are especially important before drawing any conclusions.
The Anatomy Ultrasound
Somewhere between 18 and 22 weeks, most pregnant people are offered a detailed anatomy ultrasound, often called the anomaly scan. This is different from the brief nuchal translucency scan done in the first trimester. The anatomy scan is a systematic survey of the baby’s organs, limbs, spine, brain, heart, kidneys, and other structures, looking for physical abnormalities rather than chromosomal ones.
Detection rates vary widely depending on the type of anomaly and who is performing the scan. A Cochrane systematic review found that a first-trimester scan detected about 38% of structural anomalies overall but caught roughly 91% of lethal ones. When first- and second-trimester scans were combined in a two-stage approach, the overall detection rate rose to about 84%.12Cochrane Database of Systematic Reviews. Accuracy of a first- and second-trimester ultrasound scan for identifying fetal anomalies in low-risk and unselected pregnancies A separate study looking at mid-trimester scans in a general population found an overall sensitivity of 44% for all abnormalities, but 61% for chromosomal abnormalities specifically, where soft markers on ultrasound can prompt further genetic testing.13PubMed. Detection of fetal abnormalities by second-trimester ultrasound screening in a non-selected population International reviews place the mid-trimester scan’s detection rate at roughly 60% for major anomalies, with higher rates for severe or lethal conditions.14Obstetrics, Gynaecology & Reproductive Medicine. The fetal anomaly screening scan: an international perspective
The takeaway is that the anatomy scan is very good at finding serious structural problems but not a guarantee. Some conditions are subtle, develop later in pregnancy, or are obscured by the baby’s position. A normal anatomy scan is reassuring but does not rule out every possible condition.
Invasive Diagnostic Tests
When a screening test raises a red flag, a definitive answer usually requires either chorionic villus sampling (CVS) or amniocentesis. These are the only prenatal tests that can confirm or rule out a chromosomal condition with near certainty.
CVS involves taking a tiny sample of placental tissue and is performed between about 10 and 13 weeks. Amniocentesis draws a small amount of amniotic fluid and is typically done at 15 weeks or later. Both provide cells that can be analyzed for the baby’s chromosomes, DNA, and sometimes metabolic conditions. In one study comparing the two, the complication profile was similar, with one pregnancy loss out of 153 CVS procedures and no losses in 155 amniocentesis procedures.15PubMed Central. Comparison of Complications of Chorionic Villus Sampling and Amniocentesis
The question everyone wants answered is: how risky are these procedures? The honest answer is that modern procedure-related loss rates are lower than many people expect. A large cohort study found that miscarriage after amniocentesis occurred at a rate that was not statistically different from the background rate of pregnancy loss at the same gestational age.16PubMed Central. Pregnancy Loss After Amniocentesis and Chorionic Villus Sampling: Cohort Study A separate study of nearly 8,600 late CVS cases performed under ultrasound guidance reported a spontaneous abortion rate of just 0.15%.17PubMed Central. Accuracy and Safety of Late Chorionic Villus Sampling in High-Risk Pregnancies in 8599 Cases Older estimates tended to be higher, partly because earlier studies did not always separate procedure-related losses from pregnancy losses that would have happened regardless. One study that attempted to distinguish the two found a corrected procedure-related amniocentesis loss rate of about 0.86%, with risk factors including later gestational age at the time of the procedure and the presence of blood in the sample.18PubMed. Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis Minor complications like transient amniotic fluid leakage or spotting can also occur.19PubMed Central. Indications of Amniocentesis and its Early and Late Complications
When the cells from CVS or amniocentesis reach the lab, the traditional approach is a standard karyotype, which examines the chromosomes under a microscope. Increasingly, laboratories also run chromosomal microarray analysis, a technology that detects much smaller gains and losses of genetic material. In one multicenter study, microarray analysis identified about a third more clinically meaningful chromosomal abnormalities than conventional karyotyping, with results returned in roughly a week compared to about 25 days for a karyotype.20PubMed Central. Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis The trade-off is that microarray sometimes finds variants whose clinical significance is uncertain, which can create anxiety without clear guidance.
Carrier Screening
Carrier screening stands apart from other prenatal tests because it tests the parents, not the baby. It looks at whether one or both parents carry a recessive gene variant that could cause a serious condition in their child if both parents happen to pass along a copy. Conditions like cystic fibrosis, sickle cell disease, and spinal muscular atrophy are among the most commonly screened. Expanded carrier screening panels now test for dozens or even hundreds of conditions at once and are increasingly offered as a routine part of reproductive care.21PubMed Central. Expanded Carrier Screening: Current Evidence and Future Directions in the Era of Population Genomics
Ideally, carrier screening happens before pregnancy so couples have the fullest range of options if both turn out to be carriers for the same condition. In practice, it is frequently done during the first trimester. If both partners carry a variant for the same recessive disorder, the pregnancy has a one-in-four chance of being affected, and the couple can decide whether to pursue diagnostic testing on the pregnancy itself. Large cohort studies in diverse populations have confirmed the clinical usefulness of expanded panels for identifying at-risk couples who would not have been flagged by traditional ethnicity-based screening.22PubMed. Clinical utility of expanded carrier screening in the preconception and prenatal population: A Chinese cohort study
Fetal Blood Type Testing
One of the newer and more practical applications of cell-free DNA technology has nothing to do with chromosomes. For pregnant people who are Rh-negative, knowing the baby’s Rh status early can determine whether they need Rh immunoglobulin injections to prevent a dangerous immune response in current or future pregnancies. Traditionally, the baby’s blood type was not known until birth, so all Rh-negative mothers received the injections as a precaution.
Cell-free DNA testing can now determine the fetal RhD genotype from a maternal blood draw as early as nine weeks. A large U.S. validation study found 100% sensitivity, correctly identifying every RhD-positive fetus, with specificity above 99%.23PubMed Central. Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort Other studies across all three trimesters have confirmed that the assay reliably predicts fetal RhD status.24Obstetrics & Gynecology. Circulating Cell-Free DNA to Determine the Fetal RHD Status in All Three Trimesters of Pregnancy First-trimester testing showed 100% sensitivity and roughly 95% specificity in one cohort of over 400 samples.25PubMed. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy Several European countries have already integrated this test into routine care, sparing Rh-negative women carrying Rh-negative babies from unnecessary injections.
When NIPT Accidentally Finds Maternal Cancer
Because the cell-free DNA in a pregnant person’s blood is a mixture of placental and maternal fragments, NIPT sometimes stumbles on something unexpected about the mother rather than the baby. In rare cases, unusual patterns of chromosomal gains and losses across multiple chromosomes turn out to be caused by a previously undiagnosed maternal tumor shedding its own DNA into the bloodstream.26PubMed Central. Non-invasive prenatal testing: when results suggests maternal cancer The circulating tumor DNA distorts the NIPT readout, sometimes making the test uninterpretable for fetal aneuploidy and sometimes producing a pattern of multiple false-positive flags that does not match any known fetal condition.27Clinical Chemistry. Incidental Detection of Maternal Neoplasia in Noninvasive Prenatal Testing
This is a genuinely strange byproduct of a test designed to look at babies. When an NIPT result comes back with multiple unusual flags that do not add up to a recognizable fetal pattern, providers may recommend maternal follow-up including imaging. In some documented cases, the NIPT finding led to early-stage cancer diagnoses that might not have been caught until later. It is rare, but it underscores how the biology of cell-free DNA testing extends beyond its original intended use.
Prenatal Testing After IVF with Genetic Testing
Couples who conceive through in vitro fertilization sometimes have their embryos genetically tested before transfer, a process called preimplantation genetic testing. You might wonder whether prenatal screening is still needed if the embryo was already tested. The answer from most genetic counselors is yes, though the rationale is more about caution than expectation of a problem. Embryo biopsy analyzes only a few cells, and biological factors like mosaicism within the embryo can occasionally lead to a misdiagnosis. Standard counseling still recommends confirmatory prenatal testing, usually via CVS or amniocentesis, following preimplantation genetic testing for single-gene conditions.28PubMed. The role of prenatal diagnosis following preimplantation genetic testing for single-gene conditions In practice, the rate of discordant results is low, but the consequences of a missed diagnosis are significant enough that the extra step is widely considered worthwhile.
The Role of Genetic Counseling
Prenatal testing generates information that can be genuinely difficult to sit with. Screening results express risk as probabilities, not certainties, and many people find that ambiguity harder to cope with than they anticipated. Research on the psychological experience of prenatal testing has found that anxiety tends to peak before and immediately after genetic counseling and testing, then gradually returns to normal levels, though perceived risk often remains higher than actual risk even after counseling.29PubMed. Psychological response to prenatal genetic counseling and amniocentesis
Genetic counselors are trained to present options without steering the decision. Studies of patients who worked with prenatal genetic counselors have found high satisfaction with the decision-making process, with patients describing feeling supported but not pushed toward a particular choice.30PubMed. Patient decision-making and the role of the prenatal genetic counselor: An exploratory study If you receive an abnormal screening result, a genetic counselor can walk you through what it means in your specific situation, what follow-up testing would look like, and what the range of outcomes might be. This is one area where a conversation with a specialist tends to be far more useful than a late-night internet search.
Access and Cost Gaps
Not everyone has equal access to the full menu of prenatal testing. NIPT, in particular, varies widely in how it is funded across different healthcare systems. In the Netherlands, a study of over 156,000 pregnant women found that NIPT uptake in socioeconomically disadvantaged neighborhoods was about 20%, compared to nearly 48% in other areas. Women living outside disadvantaged neighborhoods were roughly three and a half times more likely to choose NIPT.31PubMed Central. Non‐invasive prenatal test uptake in socioeconomically disadvantaged neighborhoods In Australia, healthcare professionals have flagged similar concerns, identifying cost as a major barrier, particularly for people in remote communities or with fewer financial resources.32PubMed Central. Disparities in integrating non-invasive prenatal testing into antenatal healthcare in Australia: a survey of healthcare professionals
In the United States, insurance coverage for NIPT has expanded in recent years, but out-of-pocket costs still vary. Some insurers cover it only for pregnancies deemed high-risk based on age or screening results, while others have moved toward universal coverage. The practical effect is that the testing options available to you can depend as much on your zip code and insurance plan as on your clinical situation. If cost is a concern, it is worth asking your provider directly what is covered before assuming a test is or is not available to you.